BiotechTube

Liposomal Annamycin (L-Annamycin)

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sarcoma,Soft Tissue

Conditions

Sarcoma,Soft Tissue, Pulmonary Metastasis

Trial Timeline

Jun 5, 2021 → Aug 6, 2024

NCT ID
NCT04887298

About Liposomal Annamycin (L-Annamycin)

Liposomal Annamycin (L-Annamycin) is a phase 1/2 stage product being developed by Moleculin Biotech for Sarcoma,Soft Tissue. The current trial status is completed. This product is registered under clinical trial identifier NCT04887298. Target conditions include Sarcoma,Soft Tissue, Pulmonary Metastasis.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04887298Phase 1/2Completed

Competing Products

20 competing products in Sarcoma,Soft Tissue

See all competitors
ProductCompanyStageHype Score
Tc99m-tilmanoceptNavidea BiopharmaceuticalsPhase 1
25
Azenosertib + GemcitabineZentalis PharmaceuticalsPhase 1/2
33
Olaratumab + Doxorubicin + Ifosfamide + MesnaEli LillyPhase 1
33
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 1/2
33
AbemaciclibEli LillyPhase 2
52
Abemaciclib + PlaceboEli LillyPhase 3
77
cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acidChugai PharmaceuticalPhase 3
77
PLX3397 + sirolimusDaiichi SankyoPhase 1/2
41
exatecan mesylateDaiichi SankyoPhase 2
52
efatutazoneDaiichi SankyoPhase 2
52
soblidotinDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
LinsitinibAstellas PharmaPhase 2
52
Fluzoparib+ DalpiciclibSun PharmaceuticalPhase 2
52
Anlotinib HydrochlorideSun PharmaceuticalPhase 2
52
Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+VincristineSun PharmaceuticalPhase 2
52
irinotecan liposome (II) + temozolomide + fluzoparibSun PharmaceuticalPhase 2
52
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
77
EribulinEisaiPhase 2
52
Lenvatinib + Ifosfamide + Etoposide + LenvatinibEisaiPhase 2
52

Other Products from Moleculin Biotech

Placebo in combination with Cytarabine Injection + Liposomal Annamycin Injection in combination with Cytarabine Injection + Liposomal Annamycin Injection in combination with Cytarabine Injection + Liposomal Annamycin for Injection in combination with Cytarabine Injection.Phase 2/3
57
STAT3 Inhibitor WP1066Phase 2
44
Liposomal Annamycin + CytarabinePhase 1/2
33
Liposomal AnnamycinPhase 1/2
33
Liposomal AnnamycinPhase 1/2
33